Parallax Health Sciences Inc. announced it has received preliminary approval for registration into the U.S. Government’s System for Award Management, (“SAM”) as part of the Company’s efforts to work with the Center for Disease Control and Prevention, (“CDC”) in Atlanta, Georgia to obtain a contract grant with their Small Business Group for the Company’s Immunoassay diagnostics analyzer to detect the Coronavirus, (“COVID-19”). As previously announced, these efforts coincide with the Company’s strategic initiative for the creation of a rapid screening test on its VT-1000 diagnostics device for COVID-19 that when soon available will produce results within 15 minutes. The Company has already received 26-Federal Drug Administration, (“FDA”) 510(K) approvals for biomarkers used in conjunction with the VT-1000 desktop unit. The FDA approved 510(K) tests include the following: Rotacube (Rotavirus); Rubella-Cube TM; Cmv-Cube TM; Target Quantitative, Hcg; Target Strep A (Streptococcus Spp.); V-Trend Im Test (infect mononucleosis); Target Reader; Target Cardiac, Ck-Mb; Target Troponin 1; Target C-Reactive Protein Test – 1; Target C-Reactive; Protein Test – 3; Target Myoglobin; Target Aso Test; Pregnancy, HcG; Target Hcg; Target Quantitative Hog One Step; V-Trend Target Rf Test; Blue Dot Test Pregnancy; Target Cocaine Metabolites-R Test; Target Cocaine Metabolites-V Test; Target Cannabinoids-R Test; Target Cannabinoids-V Test; Target Amphetamines/Methamphetamines-R Test; Target Amphetamines/Methamphetamines-V Test; Target Opiate-R Test; Target Opiate-V Test. The Company’s integrated remote patient monitoring and diagnostic platform can be useful to assess and comfort patients in alternative settings such as their home, and also for determining which patients need to be seen in the hospital or if urgent care is appropriate. The Company’s Good Health Outcomes™ platform can enable healthcare providers to treat isolated patients and help to prevent the spread of what is becoming an extremely contagious virus.